Differences in Carotid Intima-Media Thickness (CIMT) In Patients With Newly Diagnosed Hypertension, and Chronic Hypertensive Patients Treated by Calcium Channel Blockers (CCB) or Angiotensin Converting Enzyme (ACE)-Inhibitors


  • Ni Luh Tantri Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya – dr. Saiful Anwar Hospital, Malang
  • Achmad Rudijanto Endocrinology, Metabolic and Diabetes, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang
  • Nur Samsu Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya – dr. Saiful Anwar Hospital, Malang
  • Wursito Wursito Echocardiography, Department of Cardiology, Faculty of Medicine, Universitas Brawijaya, Malang




hypertension, atherosclerosis, CIMT, ACE-inhibitors, Calcium Channel Blockers



Hypertension is a significant risk factor for cardiovascular diseases. It closely related to the inflammatory process and resulting in chronic inflammation, which had a critical role in the progression of atherosclerosis. Carotid Intima-Media Thickness (CIMT) was known as a surrogate marker of atherosclerosis. Anti-hypertensive drugs are expected to affect CIMT. Aim: to examine the difference CIMT between newly diagnosed hypertension and chronic hypertensive treated by ACE-I or CCB. Method: this cross-sectional study was conducted on 12 newly diagnosed hypertensive patients (control or group 1), 9 hypertensive patients treated by CCB (group 2), and 9 hypertensive patients treated by ACE-I (group 3). Their hypertensive condition was controlled at least for 6 months. We compared CIMT of patients and Tumour Necrosis Factor Alfa (TNF-α) also Interleukin-6 (IL-6) among the groups. Result: there was a significant difference in CIMT between the group 1 and 2 (0.86 vs 0.70; p = 0.027), group 1 and 3 (0.86 vs 0.69; p = 0.018). There was no significant difference between group 2 and 3 (0.70 vs 0.69; p = 0.88). There was no association between CIMT and TNF-α, IL-6, Low-Density Lipoprotein (LDL), triglycerides (TGs) levels, and body mass index (BMI), systolic blood pressure. Conclusion: we found that the CIMT of the control group was thicker than those of the treatment groups. Moreover, differences in the thickness of CIMT of the three groups were not associsted with level of TNF-α, IL-6, TG, and LDL, also BMI, and systolic blood pressure.


Watson RE, DiPette DJ, Sarikonda VK, Opara OC. Experimental Animal Models of Hypertension. In: Joseph IL, Black HR, Goodfriend TR, Sowers JR, Weber AB, editors. Hypertension Primer: The Essentials of High Blood Pressure Editors. Iowa: Lippincot Williams & Wilkins Inc. 2003; 3: (2-124). [PMID:20409957.https://doi.org/10.1016/ j.jash.2009.02.003.]

Boos CJ and Lip G.Y.H. “Is Hypertension an Inflammatory Process?†Current Pharmaceutical Design. 2006; 12: 1623. [PMID: 16729874.


Jian-Jun L. Inflammation in hypertension: Primary evidence. Chinese medical journal. 2006; 119.1215-21. [PMID: 16863616. https://doi.org/10.1097/00029330-200607020-00016.]

Hilgers K. Monocytes/Macrophages in Hypertension. J Hypertension. 2002; 20: 593-596 [PMID: 11910288. https://doi.org/10.1097/00004872-200204000-00010]

Montecucco F, Pende A, Quercioli A, Mach F. Inflammation in the pathophysiology of essential hypertension. Journal of Nephrology. 2011 Jan-Feb; 24(1):23-34.[PMID:20437401. https://doi.org/10.5301/jn.2010.4729]

Bautista L, Vera LM, Arenas IA, Gamarra G. Independent Association between Inflammatory Markers (C Reactive Protein, Interleukin-6, and TNF-α) and Essential Hypertension. Journal of Human Hypertension. 2005; 19:149-154. [PMID:15361891. https://doi.org/10.1038/sj.jhh.1001785]

Kim KI, Lee JH, Chang HJ, et al. Association between Blood Pressure Variability and Inflammatory Marker in Hypertensive Patients. Circ J. 2008; 72 (2): 293-8 [PMID: 18219169 https://doi.org/10.1253/circj.72.293]

Libby P, Ridker PM, and Maseri A. Inflammation, and Atherosclerosis. Circulation. 2002; 26; 420 (6917):868-74 [PMID: 11877368. 10.1161/hc0902.104353]

Libby P. Inflammation in atherosclerosis. Nature. 2002. 420(868-872).[PMID:12490960. https://doi.org/10.1038/nature01323]

Groot ED, Hovingh GK, Wiegman A, Duriez P, Smit AJ, Fruchart JC, et al. Measurement of Arterial Wall Thickness as a Surrogate Marker for Atherosclerosis. Circulation. 2004; 109(23 Suppl 1): III33-8. [PMID: 15198964 https://doi.org/10.1161/01.CIR.0000131516.65699.ba]

Zanchetti A, Hennig M, Hollweck R, Bond G, Tang R, Cuspidi C, et al. Baseline Values but Not Treatment-Induced Changes in Carotid Intima-Media Thickness Predict Incident Cardiovascular Events in Treated Hypertensive Patients Findings in the European Lacidipine Study on Atherosclerosis (ELSA). Circulation. 2009 120(12):1084-90.[PMID:19738145 https://doi.org/10.1161/CIRCULATIONAHA.108.77311]

Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal Plus Medial Thickness of The Arterial Wall: A Direct Measurement with Ultrasound Imaging. Circulation .1986; 74(6):1399-406.[PMID:3536154. https://doi.org/10.1161/01.cir.74.6.1399]

Okazaki S, Furukado S, Abe Y, Tanaka M, Miwa K, Yamagami H, et al. Association of Inflammatory Markers and Carotid Intima-Media Thickness with the Risk of Cardiovascular Events in High-Risk Patients. Cerebrovasc Dis.2010;30(2):180-7.[PMID:20588013. https://doi.org/10.1159/000317106]

Stein JS, Korcarz CE, Hurst RT, et al. Use of Carotid Ultrasound to Identify Subclinical Vascular Disease and Evaluate Cardiovascular Disease Risk: a Consensus Statement from the American Society of Echocardiography Carotid Intimaâ€Media Thickness Task Force. J Am Soc Echocardiography. 2008; 91: 93– 111. [PMID:18261694. https://doi.org/10.1016/j.echo.2007.11.011]

Mancini, GB, Henry, GC, Macaya, C, et al. Angiotensin-Converting Enzyme Inhibition with Quinapril Improves Endothelial Vasomotor Dysfunction in Patients with Coronary Artery Disease: The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation. 1996; 94(3):258-65. [PMID: 8759064. https://doi.org/10.1161/01.CIR.94.3.258]

Staessen, JA, Wang JG, and Thijs L. Cardiovascular Protection and Blood Pressure Reduction: A Meta-Analysis. Lancet. 2001; 20:358(9290):1305-15. [PMID:11684211 https://doi.org/10.1016/S0140-6736(01)06411-X]

Wang JG, Staessen JA, Li Y, et al. Carotid Intima-Media Thickness, and Antihypertensive Treatment. Stroke. 2006; 37(7):1933-40 [PMID:16763185. https://doi.org/10.1161/01.STR.0000227223.90239.13]

Plank MJ, DJN Wall, and T David. Atherosclerosis and Calcium Signalling in Endothelial Cells. Progress in Biophysics and Molecular Biology. 2006; 91(3):287-313 [PMID:16171849. https://doi.org/10.1016/j.pbiomolbio.2005.07.005]

Stamler R, Ford CE, and Stamler J. Why Do Lean Hypertensives Have Higher Mortality Rates Than Other Hypertensives? Findings of the Hypertension Detection and Follow-up Program. North Western University Medical School. 1991; 17(4):553-64 [PMID: 2013482. DOI: https://doi.org/10.116/01.hyp.17.4.553]

Lawes CMM, Bennett DA, Feigin VL, Rodgers A. Blood Pressure and Stroke: An Overview of Published Reviews. Stroke. 2004; 35:776–785 [PMID: 15053002. https://doi.org/10.1161/01.STR.0000116869.64771.5A]

Christopher G and Joseph W. Atherosclerosis: The Road Ahead. Cell. 2001; 104(4):503-16. [PMID: 11239408. https://doi.org/10.1016/s0092-8674(01)00238-0]

Spieker L, Noll G & Ruschitzka F, et al. Working under pressure: The vascular endothelium in arterial hypertension. Journal of human hypertension. 2002;14.617-30. [PMID: 11095155. https://doi.org/10.1038/sj.jhh.1001012]

Shetty S, George P, Venkatesha B & Alva, Jayaprakash. A Study to Correlate Carotid Intima Thickness by B-Mode Ultrasonography in Patients Documented with Coronary Artery Disease. Heart views: the official journal of the Gulf Heart Association. 2011; 12(4): 157–160. [PMID: 22574241. https://doi.org/10.4103/1995-705X.90902]

Ainsworth, Craig & Blake, Christopher & Tamayo, Arturo & Beletsky, Vadim & Fenster, Aaron & Spence, J. David. 3D Ultrasound Measurement of Change in Carotid Plaque Volume A Tool for Rapid Evaluation of New Therapies. Stroke. 2005; a Journal of Cerebral Circulation. [PMID: 1608185736. https://doi.org/10.1161/01.STR.0000178543.19433.20]

Wang JG, Staessen JA, Li Y, et al. Carotid Intima-Media Thickness and Antihypertensive Treatment A Meta-Analysis of Randomized Controlled Trials. Stroke. 2006; 37(7):1933-40.[PMID:16763185. https://doi.org/10.1161/01.STR.0000227223.90239.13]

Lai YM, Fukuda N, Su JZ, et al. Novel Mechanisms of the Antiproliferative Effects of Amlodipine in Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats. Hypertens Res. 2002; 25(1):109-15 [PMID: 11924715. https://doi.org/ 10.1291/hypres.25.109]

Julius S, Weber MA, Kjeldsen SE, et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial Outcomes in Patients Receiving Monotherapy. Hypertension. 2006; 48(3):385-91.[PMID:16864741. https://doi.org/10.1161/01.HYP.0000236119.96301.f2]

Mason, RP, Marche P, and Hintze TH. Novel Vascular Biology of Third-Generation L-Type Calcium Channel Antagonists Ancillary Actions of Amlodipine. Arterioscler Thromb Vasc Biol. 2003; 23(12):2155-63 [PMID: 14512371. https://doi.org/10.1161/01.ATV.0000097770.66965.2A]

Pitt B, Byington RP, Furberg CD, et al. Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events. Circulation 2000; 102(13):1503-10. [PMID: 11004140. https://doi.org/10.1161/01.CIR.102.13.1503]

Detry J. Amlodipine and the Total Ischemic Burden: Circadian Anti Ischemia Program in Europe (CAPE) Trial-Methodology, Safety, and Toleration. The Steering Committee Members and All of the Investigators. Cardiology. 1994; 85 Suppl 2:24-30. [PMID: 7736484. https://doi.org/10.1159/000177044]

Jørgensen B, Simonsen S, Endresen K et al. Restenosis and Clinical Outcome in Patients Treated with Amlodipine After Angioplasty: Results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). JACC 2000;35(3):592-9 [PMID:10716459.https://doi.org/10.1016/S0735-1097(99)00599-9]

Tulenko TN, Chen M, Mason PE, and Mason RP. Physical Effects of Cholesterol on Arterial Smooth Muscle Membranes: Evidence of Immiscible Cholesterol Domains and Alterations in Bilayer Width during Atherogenesis. Journal of Lipid Research. 1998; 39(5):947-56 [PMID: 9610760]

Witztum J. The Oxidation Hypothesis of Atherosclerosis. Lancet.1994;344(8925):793-5.[PMID:7916078. https://doi.org/10.1016/s0140-6736(94)92346-9]

Mason R. Mechanisms of Plaque Stabilization for the Dihydropyridine Calcium Channel Blocker Amlodipine: Review of the Evidence. Atherosclerosis. 2002; 165(2):191-9.[PMID:12417269. https://doi.org/10.1016/S0021-9150(01)00729-8]

Kramsch, D. Limits of Lipid-Lowering Therapy: The Potential Benefits of Amlodipine as an Antiatherosclerotic Agent. International Journal of Cardiology. 1997; 62 Suppl 2.S119-24.[PMID: 7783112. https://doi.org/10.1016/S0167-5273(97)00249-0]

Chen L, Haught WH, Yang B, et al. Preservation of Endogenous Antioxidant Activity and Inhibition of Lipid Peroxidation as Common Mechanisms Of Antiatherosclerotic Effects Of Vitamin E, Lovastatin And Amlodipine. J Am Coll Cardiol. 1997; 30(2):569-75.[PMID:9247534. https://doi.org/10.1016/S0735-1097(97)00158-7]

Mason RP, Walter MF, Trumbore MW, Olmstead EG Jr, Mason PE. Membrane Antioxidant Effects Of The Charged Dihydropyridine Calcium Antagonist Amlodipine. J Mol Cell Cardiol. 1999; 31(1):275-81. [PMID: 10072734. https://doi.org/10.1006/jmcc.1998.0867]

Henry P. Antiperoxidative Actions of Calcium Antagonists and Atherogenesis. J Cardiovasc Pharmacol. 1991; 18: p. S6-S10. [PMID: 1723459]

Fan J and Watanabe T. Inflammatory Reactions in the Pathogenesis of Atherosclerosis. J Atheroscler Thromb. 2003;10(2):63-71.[PMID:12740479. https://doi.org/10.5551/jat.10.63]

Hansson GK, Libby P, Schönbeck U, Yan ZQ. Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis. Circ Res. 2002; 91(4):281-91. [PMID: 12193460 https://doi.org/10.1161/01.res.0000029784.15893.10]

Bautista L. Inflammation, Endothelial Dysfunction, and the Risk of High Blood Pressure: Epidemiologic and Biological Evidence. Journal of Human Hypertension. 2003; 17(4):223-30.[PMID:12692566. https://doi.org/10.1038/sj.jhh.1001537]

Chae CU, et al. Blood Pressure, and Inflammation in Apparently Healthy Men. Hypertension. 2001. 38: p. 399-403.[PMID:11566912. https://doi.org/10.1161/01.HYP.38.3.399]

Gorelick PB. Stroke Prevention Therapy beyond Antithrombotics: Unifying Mechanisms in Ischemic Stroke Pathogenesis and Implications for Therapy. Stroke 2002; 33(3):862-75.[PMID:11872916. https://doi.org/10.1161/hs0302.103657]

Lakka TA, Salonen R, Kaplan GA, Salonen JT. Blood Pressure and the Progression of Carotid Atherosclerosis in Middle-Aged Men. Hypertension. 1999; 34(1):51-6 [PMID: 10406823. https://doi.org/10.1161/01.hyp.34.1.51]

Schieffer B, M Luchtefeld, and S Braun. Role Of NAD(P)H Oxidase In Angiotensin II-Induced JAK/ STAT Signalling And Cytokine Induction. Circ Res. 2000; 87(12):1195-201. [PMID:11110778. https://doi.org/10.1161/01.res.87.12.1195]

Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of Angiotensin II and Interleukin 6 in Human Coronary Atherosclerotic Plaques Potential Implications for Inflammation and Plaque Instability. Circulation. 2000; 101(12):1372-8. [PMID:10736279. https://doi.org/10.1161/01.cir.101.12.1372]

Vanden B W, Vermeulen L, De Wilde G, De Bosscher K, Boone E, Haegeman G, et al. Signal Transduction by Tumor Necrosis Factor And Gene Regulation Of The Inflammatory Cytokine Interleukin-6. Biochem Pharmacol. 2000; 60(8):1185-95. [PMID:11007957.https://doi.org/10.1016/s0006-2952(00)00412-3]

Tilg H and Moschen A. Adipocytokines: Mediators Linking Adipose Tissue, Inflammation, and Immunity. Nat Rev Immunol. 2006; 6(10):772-83. [PMID: 16998510. https://doi.org/10.1038/nri1937]

Romano M, Sironi M, Toniatti Cet al. Role Of IL-6 And Its Soluble Receptor In Induction Of Chemokines And Leukocyte Recruitment. Immunity. 1997; 6(3):315-25. [PMID: 9075932 https://doi.org/10.1016/s1074-7613(00)80334-9]

Wisithphrom K, Murray PE, Windsor LJ. Interleukin- 1 Alpha Alters The Expression Of Matrix Metalloproteinases And Collagen Degradation By Pulp Fibroblasts. J Endod .2006; 32(3):186-92. [PMID: 16500223 https://doi.org/10.1016/j.joen.2005.10.055]

Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N. Il-6 And Its Soluble Receptor Orchestrate A Temporal Switch In The Pattern Of Leukocyte Recruitment Seen During Acute Inflammation. Immunity 2001; 14(6):705-14. [PMID: 11420041. https://doi.org/10.1016/s1074-7613(01)00151-0]

Fan Y, Ye J, Shen F, Zhu Y, Yeghiazarians Y, Zhu W. Interleukin-6 Stimulates Circulating Blood-Derived Endothelial Progenitor Cell Angiogenesis In Vitro. J Cereb Blood Flow Metab. 2008; 28(1):90-8. [PMID: 17519976. https://doi.org/10.1038/sj.jcbfm.9600509]

Wang Z, Castresana MR, Newman WH. NF-kB Is Required For TNF-Alpha-Directed Smooth Muscle Cell Migration. FEBS Lett. 2001; 508(3):360-4. [PMID: 11728452 https://doi.org/10.1016/s0014-5793(01)03109-x]

Ikeda U, Ikeda M, Oohara Tet al. Interleukin 6 Stimulates Growth of Vascular Smooth Muscle Cells In A PDGF-Dependent Manner. Am J Physiol. 1991; 260(5 Pt 2): H1713-7. [PMID: 1709793 https://doi.org/10.1152/ajpheart.1991.260.5.H1713]

Goldblatt P.J., Gohara A.F. Renal vascular diseases: Their relationship to hypertension. In: Didio L.J.A., Motta P.M. (eds) Basic, Clinical, and Surgical Nephrology. Developments in Nephrology, vol. 8. Springer, Boston, MA. 1985; 8: 157-169. [https://doi.org/10.1007/978-1-4613-2575-8_10]

Unger T. The Role of the Renin-Angiotensin System in the Development of Cardiovascular Disease. Am J Cardiol .2002; 89(2A):3A-9A. [PMID: 11835903. https://doi.org/ 10.1016/s0002-9149(01)02321-9]

Lerman LO, Nath KA, Rodriguez-Porcel Met al. Increased Oxidative Stress in Experimental Renovascular Hypertension. Hypertension .2001;37(2Pt2):541-6.[PMID:11230332. https://doi.org/10.1161/01.hyp.37.2.541]

Hernández-Presa M, Bustos C, Ortego M, et al. Angiotensin-Converting Enzyme Inhibition Prevents Arterial Nuclear Factor-Kappa B Activation, Monocyte Chemoattractant Protein-1 Expression, And Macrophage Infiltration in A Rabbit Model of Early Accelerated Atherosclerosis. Circulation .1997; 95(6):1532-41. [PMID: 9118522 https://doi.org/10.1161/01.cir.95.6.1532]

Itoh H, et al. Multiple Autocrine Growth Factors Modulate Vascular Smooth Muscle Cell Growth Response to Angiotensin II. J Clin Invest. 1993; 91: 2268-2274. [https://doi.org/10.1172/JCI116454]

Guo RW, Yang LX, Wang H, Liu B, Wang L. Angiotensin II Induces Matrix Metalloproteinase-9 Expression Via A Nuclear Factor-Kappab-Dependent Pathway in Vascular Smooth Muscle Cells. Regul Pept 2008; 147(1-3):37-44. [PMID:18252266. https://doi.org/10.1016/j.regpep.2007.12.005]

Al-Daghri NM, Al-Attas OS, Alokail MS, et al. Gender-Specific Associations Between Insulin Resistance, Hypertension, And Markers of Inflammation Among Adult Saudis with and Without Diabetes Mellitus Type 2. Advances in Medical Sciences 2010; 55(2):179-85. [PMID: 21163756 https://doi.org/10.2478/v10039-010-0052-1]

Grund, SM. Obesity, Metabolic Syndrome, and Cardiovascular Disease. The Journal of Clinical Endocrinology & Metabolism. 1989; 89(6):2595-600. [PMID: 15181029. https://doi.org/10.1210/jc.2004-0372]

Bruunsgaard H. Physical Activity and Modulation of Systemic Low-Level Inflammation. J. Leukoc. Biol 2005; 78(4):819-35.[PMID:16033812. https://doi.org/10.1189/jlb.0505247]

Sipilä K, Moilanen L, Nieminen T, et al. Metabolic Syndrome and Carotid Intima-Media Thickness in The Health 2000 Survey. Atherosclerosis. 2009; 204: 204(1):276-81. [PMID: 18848324.https://doi.org/10.1016/j.atherosclerosis.2008.08.029]

Mathieu P, P Pibarot, and JP Després. Metabolic Syndrome: The Danger Signal in Atherosclerosis. Vascular Health and Risk Management. 2006; 2: 285-302. [PMID: 17326334]

Kandil ME, Anwar G, Fatouh A, Salama N, et al. Relation between Serum Homocysteine and Carotid Intima-Media Thickness in Obese Egyptian Children. Journal of Clinical and Basic Cardiology. 2010; 13:8-11. [Corpus ID: 55710339]

Thomas R, et al. Intima-Media Thickness in Childhood Obesity, Relations to Inflammatory Markers, Glucose Metabolism, And Blood Pressure. Metabolism. 2006; 55: 113-8 [https://doi.org/10.1016/j.metabol.2005.07.016]

Li S, Chen W, Srinivasan SR, Bond MG, Tang R, Urbina EM, et al. Childhood Cardiovascular Risk Factors and Carotid Vascular Changes in Adulthood the Bogalusa Heart Study. JAMA. 2003; 290(17):2271-6. [PMID: 14600185. https://doi.org/10.1001/jama.290.17.2271]

Steinberg D. Atherogenesis in Perspective: Hypercholesterolemia and Inflammation as Partner in Crime. Nat Med. 2002; 8(11):1211-7. [PMID: 12411947 https://doi.org/10.1038/nm1102-1211]

Steinberg D. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation. 1997;95(4):1062-71.[PMID:9054771. https://doi.org/10.1161/01.cir.95.4.1062]

Itabe H. Oxidative Modification of LDL: Its Pathological Role in Atherosclerosis. Clin Rev Allerg Immunol. 2009; 37(1):4-11 [PMID: 18987785. https://doi.org/10.1007/s12016-008-8095-9]

Itabe H, Ueda M. Measurement of Plasma Oxidized Low-Density Lipoprotein and its Clinical Implications. J Atheroscler Thromb. 2007; 14(1):1-11. [PMID: 17332686. https://doi.org/10.5551/jat.14.1]

Nauck M, Warnick GR, Rifai N. Methods for Measurement of LDL-Cholesterol: A Critical Assessment of Direct Measurement by Homogeneous Assays versus Calculation. Clinical Chemistry. 2002; 48(2):236-54. [PMID: 11805004]

Lester C, et al. Atherosclerotic Assault. Eukaryon, 2006. 2: p. 40-46.

Jawien J. New Insight into Immunological Aspect of Atherosclerosis. Archiwum Medycyny Wewnetrznej 2008; 118: 127-131 [PMID:18476459]

Bots ML, Baldassarre D, Simon A, de Groot E, O'Leary DH, Riley W et al. Carotid Intima-Media Thickness And Coronary Atherosclerosis: Weak Or Strong Relations? European Heart Journal 2007; 28(4):398-406 [PMID: 17277033. https://doi.org/10.1093/eurheartj/ehl482]

Nissen SE, Tuzcu EM, Libby P, et al. Effect of Antihypertensive Agents on Cardiovascular Events in Patients with Coronary Disease and Normal Blood Pressure the CAMELOT Study: A Randomized Controlled Trial. JAMA 2004; 292(18):2217-25. [PMID:15536108.https://doi.org/10.1001/jama.292.18.2217]




How to Cite

Tantri, N. L., Rudijanto, A., Samsu, N., & Wursito, W. (2020). Differences in Carotid Intima-Media Thickness (CIMT) In Patients With Newly Diagnosed Hypertension, and Chronic Hypertensive Patients Treated by Calcium Channel Blockers (CCB) or Angiotensin Converting Enzyme (ACE)-Inhibitors. Clinical and Research Journal in Internal Medicine, 1(1), crjim, 5–18. https://doi.org/10.21776/ub.crjim.2020.001.01.2